For those who may not recall, the DEA had an opportunity to review medical cannabis last year as part of two petitions that requested it be removed as a Schedule 1 drug. Schedule 1 drugs, like LSD and heroin, are defined as having no medical benefits and are entirely illegal. After review, the DEA declined to reschedule marijuana, with the regulatory agency citing a lack of clinical benefit and risk data in its decision. The DEA also noted that a lack of marijuana use oversight steered it away from rescheduling the Marijuana Stocks drug. This brings up one of the great Catch-22s of medical marijuana: The DEA wants more clinical data from Food and Drug Administration-approved trials, but researchers can’t get these studies off the ground because its Schedule 1 status is so restrictive. The federal government is also unlikely to make things easier for drug developers. Even though President Trump threw his support behind medical marijuana during his campaign, his newly appointed attorney general, Jeff Sessions, is possibly the biggest opponent on Capitol Hill of its expansion (medically or recreationally). As long as Sessions sits on Trump’s cabinet, any easing of federal restrictions seems very unlikely. So, what does this mean for marijuana stocks and patients?